Clinical and Pharmacokinetic Risk Factors for High-dose Methotrexate-induced Toxicity in Children with Acute Lymphoblastic Leukemia: A Logistic Regression Analysis

References

• Abromowitch M, Ochs J, Pui CH, et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X. Med Pediatr Oncol 1988; 16: 297–303.
   PubMedGoogle Scholar
• Borsi JD, Moe PJ. A comparative study on the pharmacoki-netics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 1987; 60: 5–13.
   Google Scholar
• Abromowitch M, Ochs J, Pui CH, Fairclough D, Murphy SB, Rivera GK. Efficacy of high-dose methotrexate in childhood acute lymphoblastic leukemia: analysis by contemporary risk classifications. Blood 1988; 71: 866–9.
   PubMed Web of Science ®Google Scholar
• Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977; 4: 87–101.
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Moccio DM. Pharmacokinetic basis for differ-ences in methotrexate sensitivity of normal proliferative tis-sues in the mouse. Cancer Res 1980; 40: 1230–4.
   PubMed Web of Science ®Google Scholar
• Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharma-col 1979; 3: 161–6.
   Google Scholar
• Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630–4.
   Google Scholar
• Perez C, Wang YM, Sutow WW, Herson J. Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials 1978; 1: 107–11.
   PubMedGoogle Scholar
• Borsi JD, Csdki C, Nal C, Ferencz T, Schuler D. Toxicity of high-dose methotrexate therapy. In: Riccardi R, Borsi J, eds. The role of clinical pharmacology in pediatric oncology. San Francisco: 6th Pharmacology Workshop Satellite to XXV SIOP Meeting, 1993: 112–8.
   Google Scholar
• Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE. Effect of hydration on methotrexate plasma con-centration in children with acute lymphoblastic leukemia. J Clin Oncol 1988; 6: 797–801.
   Google Scholar
• Relling MV, Fairclough D, Ayers D, et al. Patient character-istics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12: 1667–72.
   PubMed Web of Science ®Google Scholar
• Slordal L, Kolmannskog S, Moe PJ, Prytz PS, Aarbakke J. High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. Pedi-atr Hematol Oncol 1987; 4: 33–42.
   Google Scholar
• Seidel H, Moe PJ, Nygaard R, Nygaard K, Brede W, Borsi JD. Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr He-matol Oncol 1994; 11: 165–72.
   PubMed Web of Science ®Google Scholar
• Schroeder H, Heinsvig E. Enzymatic assay for methotrexate in erythrocytes. Scand J Clin Lab Invest 1985; 45: 657–9.
   PubMed Web of Science ®Google Scholar
• Albertioni F, Rask C, Eksborg S, et al. Evaluation of clinical assays for measuring high-dose methotrexate in plasma. Clin Chem 1996; 42: 39–44.
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm 1985; 13: 185–201.
   PubMedGoogle Scholar
• Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The faces pain scale for the self-assessment of the severity of pain experienced by children: development, initial validation and preliminary investigation for ratio scale properties. Pain 1990; 41: 139–50.
   Google Scholar
• Rask C, Albertioni F, Schroeder H, Peterson C. Oral mucosi-tis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate. Relation to pharmacokinetic parameters of methotrexate. Pediatr Hematol Oncol 1996; 13: 359–67.
   PubMed Web of Science ®Google Scholar
• Perez C, Sutow WW, Wang YM, Herson J. Evaluation of overall toxicity of high-dosage methotrexate regimens. Med Pediatr Oncol 1979; 6: 219–28.
   PubMedGoogle Scholar
• Ishii E, Yamada S, Higuchi S, et al. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia. Med Pediatr Oncol 1989; 17: 429–32.
   PubMedGoogle Scholar
• Oliff A, Bleyer WA, Poplack DG. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol 1979; 2: 225–6.
   Google Scholar
• Exadaktylos P, Reiss T, Schobess R, Hommann M, Höhne S, Beck A. Acute hepatotoxicity with intermediate-dose methotrexate in children with leukemia and non-Hodgkin's lymphoma. Klin Paediatr 1994; 206: 315–8.
   Google Scholar
• McIntosh S, Davidson DL, O'Brien RT, Pearson HA. Methotrexate hepatotoxicity in children with leukemia. J Pe-diatr 1977; 90: 1019–21.
   Google Scholar
• Allegra CJ. Antifolates. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: Principles and practice. Philadelphia: JB Lippincott Company, 1990: 110–53.
   Google Scholar
• Diehl V, Kotz R, Salzer M, et al. Report on various clinical studies on high-dose methotrexate in Europe (NON-EORTC). Onkologie 1981; 4: 308–19.
   PubMedGoogle Scholar
• Frickel C, Wolfrom C, Belz S, Henze G. Pharmacokinetics of MTX, 7-OHMTX and rescue folates in HDMTX treatment with low leucovorin rescue. Proc Med Pediatr Oncol 1993; 21: 568 (abstr P55).
   Google Scholar
• Lankelma J, Van-der-Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer ther-apy. Cancer Lett 1980; 9: 133–42.
   PubMed Web of Science ®Google Scholar
• Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate. Cancer Chemother Pharmacol 1985; 15: 101–4.
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Smeland E, Huseby NE, Eide TJ, Aarbakke J. Acute hepatotoxicity after high-dose methotrexate adminis-tration to rats. Pharmacol Toxicol 1991; 69: 132–9.
   Google Scholar
• Smeland E, Bremnes RM, Andersen A, et al. Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. Cancer Chemother Pharmacol 1994; 34: 119–24.
   PubMed Web of Science ®Google Scholar
• Fabre G, Matherly LH, Fabre I, Cano JP, Goldman ID. Interactions between 7-hydroxymethotrexate and methotrex-ate at the cellular level in the Ehrlich ascites tumor in vitro. Cancer Res 1984; 44: 970–5.
   Google Scholar
• Chello PL, Sirotnak FM, Dorick DM, Donsbach RC. Thera-peutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells. Cancer Res 1977; 37: 4297–303.
   PubMed Web of Science ®Google Scholar